KURA - Kura Oncology doses first patient in early-stage KO-539 leukemia study

Kura Oncology (KURA) announces that the first patient has been dosed in the Phase 1b portion of KOMET-001, a Phase 1/2 clinical trial of the company’s oral, potent and selective menin inhibitor, KO-539, in patients with relapsed or refractory acute myeloid leukemia ((AML)).The Phase 1b portion of the study is designed to determine the lowest dose of KO-539 that provides maximum biologic and clinical effect in two expansion cohorts – a low dose (200 mg) and a high dose (600 mg).Both doses have demonstrated preliminary evidence of biologic and clinical activity and were determined to be safe and well tolerated in the Phase 1a portion of the study, the company said.Kura expects to enroll at least 12 patients in each of the expansion cohorts and assess the patients for safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy in order to determine the recommended Phase 2 dose.

For further details see:

Kura Oncology doses first patient in early-stage KO-539 leukemia study